FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089211897> ?p ?o ?g. }

• W2089211897 endingPage "1" @default.
• W2089211897 startingPage "1" @default.
• W2089211897 abstract "Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta NanniniDivision of Rheumatology, Misericordia e Dolce Hospital, Prato, ItalyBackground: The aim of this study was to evaluate the proportion of patients with ankylosing spondylitis maintaining clinical remission after reduction of their subcutaneous etanercept dose to 50 mg every other week compared with that in patients receiving etanercept 50 mg weekly.Methods: In the first phase of this randomized, prospective, follow-up study, all biologic-naïve patients identified between January 2005 and December 2009 as satisfying the modified New York clinical criteria for ankylosing spondylitis treated with etanercept 50 mg weekly were evaluated for disease remission in January 2010. In the second phase, patients meeting the criteria for remission were randomized to receive subcutaneous etanercept as either 50 mg weekly or 50 mg every other week. The randomization allocation was 1:1. Remission was defined as Bath Ankylosing Spondylitis Disease Activity Index < 4, no extra-axial manifestations of peripheral arthritis, dactylitis, tenosynovitis, or iridocyclitis, and normal acute-phase reactants. The patients were assessed at baseline, at weeks 4 and 12, and every 12 weeks thereafter. The last visit constituted the end of the follow-up.Results: During the first phase, 78 patients with ankylosing spondylitis (57 males and 21 females, median age 38 years, median disease duration 12 years) were recruited. In January 2010, after a mean follow-up of 25 ± 11 months, 43 (55.1%) patients achieving clinical remission were randomized to one of the two treatment arms. Twenty-two patients received etanercept 50 mg every other week (group 1) and 21 received etanercept 50 mg weekly (group 2). At the end of follow-up, 19 of 22 (86.3%) subjects in group 1 and 19 of 21 (90.4%) in group 2 were still in remission, with no significant difference between the two groups. The mean follow-up duration in group 1 and group 2 was 22 ± 1 months and 21 ± 1.6 months, respectively.Conclusion: Remission of ankylosing spondylitis is possible in at least 50% of patients treated with etanercept 50 mg weekly. After halving of the etanercept dose, remission is maintained in a high percentage of patients during long-term follow-up, with important economic implications.Keywords: ankylosing spondylitis, anti-tumor necrosis factor, etanercept, remission, dose reduction" @default.
• W2089211897 created "2016-06-24" @default.
• W2089211897 creator A5028253659 @default.
• W2089211897 creator A5059722619 @default.
• W2089211897 creator A5077870866 @default.
• W2089211897 creator A5085880704 @default.
• W2089211897 creator A5091280294 @default.
• W2089211897 date "2013-01-01" @default.
• W2089211897 modified "2023-09-27" @default.
• W2089211897 title "Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study" @default.
• W2089211897 cites W1953074743 @default.
• W2089211897 cites W1964987118 @default.
• W2089211897 cites W1966756689 @default.
• W2089211897 cites W1975137544 @default.
• W2089211897 cites W1976601340 @default.
• W2089211897 cites W1995228104 @default.
• W2089211897 cites W1995356102 @default.
• W2089211897 cites W2004646141 @default.
• W2089211897 cites W2010656216 @default.
• W2089211897 cites W2011265813 @default.
• W2089211897 cites W2018410379 @default.
• W2089211897 cites W2030187620 @default.
• W2089211897 cites W2043101237 @default.
• W2089211897 cites W2066175004 @default.
• W2089211897 cites W2077615804 @default.
• W2089211897 cites W2134280423 @default.
• W2089211897 cites W2138766095 @default.
• W2089211897 cites W2142596622 @default.
• W2089211897 cites W2148898218 @default.
• W2089211897 cites W2171675095 @default.
• W2089211897 cites W2336936581 @default.
• W2089211897 cites W2407735220 @default.
• W2089211897 cites W179140423 @default.
• W2089211897 doi "https://doi.org/10.2147/btt.s31474" @default.
• W2089211897 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3540908" @default.
• W2089211897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23319853" @default.
• W2089211897 hasPublicationYear "2013" @default.
• W2089211897 type Work @default.
• W2089211897 sameAs 2089211897 @default.
• W2089211897 citedByCount "31" @default.
• W2089211897 countsByYear W20892118972013 @default.
• W2089211897 countsByYear W20892118972014 @default.
• W2089211897 countsByYear W20892118972015 @default.
• W2089211897 countsByYear W20892118972016 @default.
• W2089211897 countsByYear W20892118972017 @default.
• W2089211897 countsByYear W20892118972018 @default.
• W2089211897 countsByYear W20892118972019 @default.
• W2089211897 countsByYear W20892118972020 @default.
• W2089211897 countsByYear W20892118972021 @default.
• W2089211897 countsByYear W20892118972022 @default.
• W2089211897 countsByYear W20892118972023 @default.
• W2089211897 crossrefType "journal-article" @default.
• W2089211897 hasAuthorship W2089211897A5028253659 @default.
• W2089211897 hasAuthorship W2089211897A5059722619 @default.
• W2089211897 hasAuthorship W2089211897A5077870866 @default.
• W2089211897 hasAuthorship W2089211897A5085880704 @default.
• W2089211897 hasAuthorship W2089211897A5091280294 @default.
• W2089211897 hasBestOaLocation W20892118971 @default.
• W2089211897 hasConcept C126322002 @default.
• W2089211897 hasConcept C141071460 @default.
• W2089211897 hasConcept C168563851 @default.
• W2089211897 hasConcept C188816634 @default.
• W2089211897 hasConcept C198451711 @default.
• W2089211897 hasConcept C204243189 @default.
• W2089211897 hasConcept C2776260265 @default.
• W2089211897 hasConcept C2777226972 @default.
• W2089211897 hasConcept C2777402515 @default.
• W2089211897 hasConcept C2777575956 @default.
• W2089211897 hasConcept C2778019847 @default.
• W2089211897 hasConcept C2779650986 @default.
• W2089211897 hasConcept C2780131103 @default.
• W2089211897 hasConcept C71924100 @default.
• W2089211897 hasConceptScore W2089211897C126322002 @default.
• W2089211897 hasConceptScore W2089211897C141071460 @default.
• W2089211897 hasConceptScore W2089211897C168563851 @default.
• W2089211897 hasConceptScore W2089211897C188816634 @default.
• W2089211897 hasConceptScore W2089211897C198451711 @default.
• W2089211897 hasConceptScore W2089211897C204243189 @default.
• W2089211897 hasConceptScore W2089211897C2776260265 @default.
• W2089211897 hasConceptScore W2089211897C2777226972 @default.
• W2089211897 hasConceptScore W2089211897C2777402515 @default.
• W2089211897 hasConceptScore W2089211897C2777575956 @default.
• W2089211897 hasConceptScore W2089211897C2778019847 @default.
• W2089211897 hasConceptScore W2089211897C2779650986 @default.
• W2089211897 hasConceptScore W2089211897C2780131103 @default.
• W2089211897 hasConceptScore W2089211897C71924100 @default.
• W2089211897 hasLocation W20892118971 @default.
• W2089211897 hasLocation W20892118972 @default.
• W2089211897 hasLocation W20892118973 @default.
• W2089211897 hasLocation W20892118974 @default.
• W2089211897 hasLocation W20892118975 @default.
• W2089211897 hasOpenAccess W2089211897 @default.
• W2089211897 hasPrimaryLocation W20892118971 @default.
• W2089211897 hasRelatedWork W1516746560 @default.
• W2089211897 hasRelatedWork W1972307658 @default.
• W2089211897 hasRelatedWork W1986679381 @default.
• W2089211897 hasRelatedWork W2169307686 @default.
• W2089211897 hasRelatedWork W2890001839 @default.

• next